GANX · NASDAQ · Biotechnology

Gain Therapeutics (GANX)

Develops allosteric medicines and rexaceract for Parkinson’s disease.

$1.84
vs last close−0.11 (−5.64%)
  1. Gain Therapeutics (GANX) Upgraded to Buy: Here's Why

    Zacks Investment Research